Masamitsu Hihara

426 total citations
7 papers, 65 citations indexed

About

Masamitsu Hihara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Masamitsu Hihara has authored 7 papers receiving a total of 65 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 1 paper in Pathology and Forensic Medicine. Recurrent topics in Masamitsu Hihara's work include Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Masamitsu Hihara is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Masamitsu Hihara collaborates with scholars based in Japan. Masamitsu Hihara's co-authors include Takeshi Kato, Kentaro Yamazaki, Takeshi Naitoh, Takayuki Yoshino, Junpei Soeda, Katsuya Tsuchihara, Takeo Sato, Eiji Oki, Kei Muro and Hiroyuki Uetake and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Value in Health.

In The Last Decade

Masamitsu Hihara

6 papers receiving 62 citations

Peers

Masamitsu Hihara
Heinz‐Gert Hoeffkes Germany
J. Douma Netherlands
Imane H. El Dika United States
Gianfranco Francioni Italy
Setareh Samimi Canada
Yumi Kosaka Japan
Joanne Hornbuckle United Kingdom
Nick Wadd United Kingdom
Sujata Rao United States
Heinz‐Gert Hoeffkes Germany
Masamitsu Hihara
Citations per year, relative to Masamitsu Hihara Masamitsu Hihara (= 1×) peers Heinz‐Gert Hoeffkes

Countries citing papers authored by Masamitsu Hihara

Since Specialization
Citations

This map shows the geographic impact of Masamitsu Hihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masamitsu Hihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masamitsu Hihara more than expected).

Fields of papers citing papers by Masamitsu Hihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masamitsu Hihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masamitsu Hihara. The network helps show where Masamitsu Hihara may publish in the future.

Co-authorship network of co-authors of Masamitsu Hihara

This figure shows the co-authorship network connecting the top 25 collaborators of Masamitsu Hihara. A scholar is included among the top collaborators of Masamitsu Hihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masamitsu Hihara. Masamitsu Hihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Harano, Kenichi, Toru Mukohara, Tomohiro Nakao, et al.. (2023). RWD94 Feasibility Study for Patient Journey Mapping for Ovarian Cancer Using Electronic Health Record Data. Value in Health. 26(6). S378–S378.
2.
Yoshino, Takayuki, Kohei Shitara, Hirofumi Yasui, et al.. (2022). Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.. Journal of Clinical Oncology. 40(17_suppl). LBA1–LBA1. 43 indexed citations
3.
Yoshino, Takayuki, Hiroyuki Uetake, Katsuya Tsuchihara, et al.. (2021). PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology. 39(3_suppl). 85–85. 7 indexed citations
4.
5.
6.
7.
Muro, Kei, Hiroyuki Uetake, Katsuya Tsuchihara, et al.. (2016). PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS3625–TPS3625. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heinz‐Gert Hoeffkes Breakdown of academic impact, for papers by J. Douma Breakdown of academic impact, for papers by Imane H. El Dika Breakdown of academic impact, for papers by Gianfranco Francioni Breakdown of academic impact, for papers by Setareh Samimi Breakdown of academic impact, for papers by Yumi Kosaka Breakdown of academic impact, for papers by Joanne Hornbuckle Breakdown of academic impact, for papers by Nick Wadd Breakdown of academic impact, for papers by Sujata Rao
Rankless by CCL
2026